Bacterial Infections  >>  Cubicin (daptomycin)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cubicin (daptomycin) / Merck (MSD)
NCT01975662: Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia

Terminated
2b
14
RoW
Daptomycin, Cubicin, Vancomycin, Vancomycin Hydrochloride
Singapore General Hospital, Singapore Clinical Research Institute
Bacteremia Due to Staphylococcus Aureus
12/15
12/15
NCT00695903: Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

Terminated
2
38
US
daptomycin, Cubicin, daptomycin for injection, vancomycin, vancocin
Cubist Pharmaceuticals LLC
Endocarditis, Bacterial, Infective Endocarditis
08/10
10/10
NCT02052388: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

Completed
2
215
US
Daptomycin, Cubicin, Brilacidin, PMX63
Cellceutix Corporation
Skin Infection, Bacterial Infection
10/14
10/14
Bacteremia, NCT01191840: Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

Completed
2
509
US, Europe
Vancomycin, Nafcillin, Oxacillin, Cloxacillin, Daptomycin, Cefazolin
Duke University, National Institutes of Health (NIH)
Bacteremia
03/17
03/17

Download Options